INS and Hypoglycemia: In a study investigating exenatide’s impact on glycemic variability and hypoglycemia, 30 patients with T1DM were randomly divided into two groups: one received a combination of exenatide (10 μg) and insulin, while the other continued with insulin therapy alone for four weeks.